Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 7Recruiting 3Unknown 2Not yet recruiting 2Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 1

Interventions

pembrolizumab 224Cyclophosphamide 192Radiotherapy 183Nivolumab 180Carboplatin 153Cisplatin 114Paclitaxel 112Dexamethasone 110Radiosurgery 104Magnetic Resonance Spectroscopy 97Surveys and Questionnaires 91Ipilimumab 81Doxorubicin 79Lenalidomide 76durvalumab 75Rituximab 75atezolizumab 72Radiation 72venetoclax 69fludarabine 68Standard of Care 68Gemcitabine 68Specimen Handling 65Etoposide 64Capecitabine 64Bevacizumab 62Oxaliplatin 59Docetaxel 58Biopsy 58Radiotherapy, Intensity-Modulated 56

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × OTHER × Duloxetine Hydrochloride × Clear all
NCT04137107 2026-01-26

Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer

Alliance for Clinical Trials in Oncology

Phase 2/3 Active not recruiting
220 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡